Author

Graeme Currie

Observed names: G. Currie, G.M. Currie

Observed institutions: Lytix Biopharma (Norway), Dynavax Technologies (United States), Gilead Sciences (United States)

OpenAlex ID: A5065124642

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

2005 · Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, et al. · New England Journal of Medicine · 531

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

2006 · Karsten Wursthorn, Marc Lutgehetmann, et al. · Hepatology · 438

PDF

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1

2005 · Yves Benhamou, Vincent Thibault, et al. · Journal of Hepatology · 80

PDF

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

2019 · Arlene O. Siefker-Radtke, Graeme Currie, et al. · Journal of Clinical Oncology · 64

Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

2019 · Andrea Necchi, Daniel E. Castellano, et al. · Journal of Clinical Oncology · 44

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

2018 · Joaquim Bellmunt, Joel Picus, et al. · Journal of Clinical Oncology · 24

Dosing guidelines for Adefovir Dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment

2002 · Wanda Knight, Sandra Hayashi, et al. · Journal of Hepatology · 23

Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22

2019 · A.O. Siefker-Radtke, I. Lugowska, et al. · Annals of Oncology · 13

Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

2019 · Begona Mellado, Daniel E. Castellano, et al. · Journal of Clinical Oncology · 9

Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naïve & experienced metastatic melanoma patients.

2017 · Abraham C.F. Leung, Shivaani Kummar, et al. · Journal of Clinical Oncology · 7

1051P Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial

2023 · S. Dalle, T.U. Marron, et al. · Annals of Oncology · 6

PDF

Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects

2002 · Brian Kearney, Wanda Knight, et al. · Journal of Hepatology · 6

A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen and trimethoprim/sulfamethoxazole

2002 · Brian Kearney, Wanda Knight, et al. · Journal of Hepatology · 6

Pd47-08 Fierce-21: Phase 2 Study of Vofatmab (b-701), a Selective Inhibitor of Fgfr3, as Salvage Therapy in Metastatic Urothelial Carcinoma (mucc)

2019 · Andrea Necchi*, Daniel Castellano, et al. · The Journal of Urology · 4

Abstract PR09: Gene expression profiling in wild-type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab

2020 · Woonyoung Choi, David McConkey, et al. · Clinical Cancer Research · 2

PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies.

2024 · Graeme Currie, Michael Leviten, et al. · Journal of Clinical Oncology

PDF

Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22

2019 · A. Siefker-Radtke, I. Lugowska, et al. · European Urology Supplements

Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)

2017 · Albert Candia, Cristiana Guiducci, et al. · Cancer Research

Adefovir dipivoxil 10 mg (ADV) results in consistent efficacy in chronic hepatitis B (CHB) patients with diverse baseline characteristics

2003 · P. Marcellin, S. Hadzyannis, et al. · Journal of Hepatology

Works count: 19

Citation count: 1,257

H-index: 9

I10-index: 8